Exploring the effects of combined CBD and THC (20:1) on sleep and brain activation in patients with insomnia disorder. Eligible participants undergo two overnight sleep studies receiving randomised active and placebo treatments. This study is being led by Professor Ron Grunstein. See here for more information.
Study site: Woolcock Institute of Medical Research, Glebe, NSW 2037
Exploring the effect of combined THC and CBD (1:1) on tics in patients with Tourette syndrome. Eligible participants will undergo two 8-week treatment periods receiving either active or placebo treatment. This study is being led by Dr Philip Mosley. See here for more information.
Access book chapters, journal articles, editorials and commentaries, and reports contributed to and produced by ACRE investigators and members
The Australian Centre
and Research Excellence
is working to develop a national research and policy framework that ensures quality and safety in the implementation of medicinal cannabis use in the community.
Access resources on medicinal cannabinoids produced by ACRE including the NSW Cannabis Medicines Prescribing Guidance to provide interim information to support NSW medical practitioners in prescribing cannabis medicines.
The Australian Centre for Cannabinoid Clinical and Research Excellence is a National Health and Medical Research Council Centre of Research Excellence.
ACRE is generously funded by the National Health and Medical Research Council through the Centre of Research Excellence scheme.
If you are interested in referring participants to the CARE NSW Trial, please see the trial registration for Cannabinoids for Symptom Control in Advanced Cancer, an Open-Label Prospective Clinical Trial in New South Wales (NSW) or the CARE NSW Trial Information for Health Professionals Fact Sheet for further information.
The CARE NSW Trial is a multi-site, state-wide clinical trial which will enrol up to 600 patients in metropolitan and regional centres across NSW. It is open to both men and women with advanced cancer who experience uncontrolled symptoms of pain and/or nausea and/or anorexia. The information collected in CARE NSW will guide the future use of cannabis medicines to control symptoms in people with advanced cancer.
Cannabinoids for Symptom Control in Advanced Cancer, an Open Label Prospective Clinical Trial in NSW.
FOR HEALTH PROFESSIONALS
Patients with advanced cancer who experience uncontrolled symptoms of pain and/or nausea and/or anorexia as well as meet the inclusion criteria are invited to participate.
The CARE NSW Trial is an open-label, prospective, Phase IV trial (which includes a Phase II pharmacokinetic component) to assess the safety and efficacy of a range of cannabis medicines on key symptoms experienced by patients with advanced cancer. This study also aims to identify the best dose and frequency of the cannabis medicine for symptom control. Gathering this evidence will guide the future prescribing of cannabis medicines for patients with advanced cancer.